查看文章

We report the case of a woman who was diagnosed with relapsing-remitting multiple sclerosis. Initially, she only received symptomatic treatment, but as her relapses became more frequent, she began disease modifying therapy for multiple sclerosis. Inteferon ß-1a was the first option, but the presence of neutralizing antibodies recommended its withdrawal after a few years. Glatiramer acetate was also forced to be resumed as severe dermatological lesions developed. Fingolimod, a new oral agent approved by the US Food and Drug Administration and the European Medicines Agency for the treatment of multiple sclerosis was chosen as an option